http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102353086-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-164 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-195 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6817 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-68 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-195 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2019-08-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-102353086-B1 |
| titleOfInvention | Novel Method for Preparing Immunotoxin |
| abstract | The present invention relates to a method for preparing an immunotoxin and a composition for treating cancer using the same, and more particularly, to an immunotoxin characterized in that a cysteine-substituted immunoglobulin mutant and PE24 introduced with a non-natural amino acid are site-specifically bound. It relates to a manufacturing method, an immunotoxin prepared by the manufacturing method, and a composition for treating cancer. According to the present invention, by using site-directed mutagenesis (site-directed mutagenesis) to introduce a reactive cysteine into a monoclonal antibody and a method for introducing a non-natural amino acid into a protein, the antigen binding of the antibody and the toxin Since it does not affect biochemical properties such as catalytic activity and can produce a homologous immunotoxin that is cytotoxic to cancer cell lines, various antibody-protein conjugates can be prepared and applied as a cancer treatment. |
| priorityDate | 2018-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 869.